2022 World Conference on Lung Cancer (ePosters)-EP08.04-004. Impact of Comorbidity Scores on Overall Survival in Advanced Non-Small Cell Lung Cancer Patients -A Real-World Experience from Eastern India

EP08.04-004. Impact of Comorbidity Scores on Overall Survival in Advanced Non-Small Cell Lung Cancer Patients -A Real-World Experience from Eastern India

Back to course

Pdf Summary

This study aimed to evaluate the impact of comorbidity scores on overall survival (OS) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) in Eastern India. The study enrolled 114 patients who were diagnosed with advanced NSCLC and received platinum-based doublet chemotherapy or targeted therapy based on molecular studies. Palliative radiotherapy was also administered when necessary.<br /><br />Comorbidities were assessed using three different scoring systems: Charlson Comorbidity Index (CCI), Simplified Comorbidity Score (SCS), and Adult Comorbidity Evaluation-27 (ACE-27). The comorbidity scores were categorized into two or three groups. The primary outcome assessed was overall survival, which was defined as the number of days from the start of anticancer therapy to the date of last follow-up or death.<br /><br />The mean age of the enrolled patients was 56.54 years, with the majority being male (68.4%) and smokers (52.6%). Adenocarcinoma was the most common histology (73.6%), followed by squamous cell carcinoma (25.4%). The median overall survival was 127 days.<br /><br />The distribution of comorbidity scores showed that 33.3% of patients had a CCI score of 0, 57% had a CCI score of 1, and 9.6% had a CCI score of 2. SCS scores of 9 and 9 were seen in 92.1% and 7.9% of patients, respectively. The majority of patients (47 subjects) had no ACE-27 comorbidity score, followed by mild (59 subjects) and moderate (12 subjects) scores. Only 3 NSCLC subjects had a severe ACE-27 score.<br /><br />The analysis of comorbidity scores and overall survival did not show any statistically significant difference. The patients with different comorbidity scores did not exhibit a significant influence on overall survival.<br /><br />In conclusion, this study's findings suggest that comorbidities may not significantly affect the overall survival of advanced NSCLC patients treated with chemotherapy or oral tyrosine kinase inhibitors.

Asset Subtitle

Srikanth Goud Mamidi

Meta Tag

Speaker Srikanth Goud Mamidi

Topic Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

Keywords

comorbidity scores

overall survival

NSCLC

chemotherapy

molecular studies

palliative radiotherapy

Charlson Comorbidity Index

Simplified Comorbidity Score

ACE-27

adenocarcinoma